4-[[3-(Carboxymethylsulfanyl)-4-hydroxynaphthalen-1-yl]sulfamoyl]benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-[[3-(Carboxymethylsulfanyl)-4-hydroxynaphthalen-1-yl]sulfamoyl]benzoic acid
• 化学式: C₁₉H₁₅NO₇S₂
• mdl: MFCD05804524
• 分子量: 433.5
• InChiKey: CIERPRDYPKVDJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  175
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• [EN] STAT DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE STAT ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020206424A1

  公开（公告）日：2020-10-08

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• SMALL MOLECULE INHIBITORS OF MCL-1 AND THE USES OF THEREOF
  申请人：WAYNE STATE UNIVERSITY

  公开号：US20140235702A1

  公开（公告）日：2014-08-21

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having sulfonamido-1-hydroxynaphthalene structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases.

  这项发明涉及药物化学领域。具体而言，该发明涉及一类新型小分子，具有磺酰胺基-1-羟基萘结构，可作为Mcl-1蛋白酶抑制剂，并可用作治疗癌症和其他疾病的治疗剂。
• Methods and compositions for treatment of fibrosis
  申请人：Baylor College of Medicine

  公开号：US10112933B2

  公开（公告）日：2018-10-30

  Embodiments of the invention include methods of treating, preventing, and/or reducing the risk of fibrosis in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction of the risk of fibrosis. In at least particular cases, the small molecules are inhibitors of STAT3.

  本发明的实施方案包括治疗、预防和/或降低有需要的个体纤维化风险的方法。在某些实施方案中，采用特定的小分子来治疗、预防和/或降低纤维化的风险。至少在特定情况下，小分子是 STAT3 的抑制剂。
• Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
  申请人：Baylor College of Medicine

  公开号：US10676455B2

  公开（公告）日：2020-06-09

  Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.

  本发明的实施方案包括治疗、预防和/或降低有需要的个体发生选自肌肉萎缩、肌无力、恶病质及其组合的疾病的风险或严重程度的方法。在某些实施方案中，采用特定的小分子来治疗、预防和/或降低肌肉萎缩的风险。至少在特定情况下，小分子是 STAT3 的抑制剂。
• Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies
  申请人：Medof M. Edward

  公开号：US11130801B2

  公开（公告）日：2021-09-28

  A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells at least one agent that modulates C3aR and/or C5aR signaling of the cells.

  一种调节表达 C3a 受体（C3aR）和 C5a 受体（C5aR）以及至少一种生长因子受体的细胞的生长因子反应的方法，包括给细胞注射至少一种能调节细胞的 C3aR 和/或 C5aR 信号转导的药剂。